Xenon's Azetukalner Delivers 'Highest Efficacy Ever' in Phase 3 Epilepsy Study, NDA Submission Planned
XENE sits 82% above its 52-week low of $26.74.
Summary
Xenon Pharmaceuticals announced highly positive topline results from its Phase 3 X-TOLE2 study of azetukalner for focal onset seizures (FOS). The study successfully met its primary endpoint, demonstrating a significant median percent change in monthly FOS frequency, with the 25 mg dose achieving a -53.2% reduction compared to -10.4% for placebo. Management highlighted that the placebo-adjusted efficacy of -42.7% in the 25 mg group exceeded expectations and may represent the highest ever observed in a pivotal epilepsy study. This critical milestone, which was anticipated in recent SEC filings, significantly de-risks the lead drug candidate. Xenon plans to submit a New Drug Application (NDA) to the FDA in Q3 2026, positioning azetukalner as potentially the only KV7 potassium channel opener for epilepsy, offering a differentiated mechanism of action and ease-of-use. This strong data provides a clear path to market and is a major positive catalyst for the company.
At the time of this announcement, XENE was trading at $48.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5B. The 52-week trading range was $26.74 to $46.99. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.